JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Altimmune Inc

Uždarymo kaina

3.96 0.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.96

Max

3.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.6M

-22M

Pardavimai

5K

Pelno marža

-442,920

Darbuotojai

59

EBITDA

-2.7M

-23M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+400% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

79M

353M

Ankstesnė atidarymo kaina

3.71

Ankstesnė uždarymo kaina

3.96

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Altimmune Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-24 18:41; UTC

Uždarbis

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025-10-24 18:31; UTC

Uždarbis

Correction to Procter & Gamble to Focus on Innovation

2025-10-24 16:25; UTC

Pagrindinės rinkos jėgos

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025-10-24 21:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-24 21:24; UTC

Rinkos pokalbiai

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025-10-24 21:07; UTC

Uždarbis

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025-10-24 20:58; UTC

Uždarbis

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025-10-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 20:40; UTC

Uždarbis

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025-10-24 20:24; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:23; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:13; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 20:07; UTC

Rinkos pokalbiai

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025-10-24 19:40; UTC

Rinkos pokalbiai

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025-10-24 19:35; UTC

Rinkos pokalbiai

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025-10-24 19:33; UTC

Uždarbis

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025-10-24 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025-10-24 18:52; UTC

Uždarbis

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:41; UTC

Uždarbis

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:03; UTC

Uždarbis

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025-10-24 18:02; UTC

Uždarbis

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025-10-24 18:00; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025-10-24 16:57; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025-10-24 16:54; UTC

Rinkos pokalbiai

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025-10-24 16:44; UTC

Rinkos pokalbiai
Uždarbis

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025-10-24 16:39; UTC

Rinkos pokalbiai
Uždarbis

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025-10-24 16:33; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:23; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 16:07; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Altimmune Inc Prognozė

Kainos tikslas

By TipRanks

400% į viršų

12 mėnesių prognozė

Vidutinis 19.75 USD  400%

Aukščiausias 25 USD

Žemiausias 12 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Altimmune Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

4

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.365 / 6.0486Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
help-icon Live chat